Crowell & Moring Lifescience Partner to Speak at First Exclusive Partnering Forum for the Industrial Cancer & Antibody Markets

Washington, D.C. – August 14, 2003: Robin Teskin, a partner with Crowell & Moring LLP, will be a panelist at the first-ever exclusive partnering conference for the industrial cancer & antibody markets, entitled "Oncology & Antibody Business Development Global Summit," to be held October 20-21 in Philadelphia, PA. The Strategic Research Institute announced that this conference expects to draw an attendance of 200+ business development leaders ranging from small to large pharma & biotech companies.

This conference offers many benefits for the business development community, including:

• Partnering topics for the small molecule & macromolecule markets;
• Focused networking and BD opportunities;
• Unparalleled market analyses & conference content; and
• Pre-arranged one-on-one meetings during conference functions.

Robin's panel discussion, entitled "Antibody Asset of Intellectual Property," will discuss intellectual property issues that are relevant to the growing antibody company sector. The session will further address how these issues can be managed in order to enhance company valuation, public offerings, investor funding, corporate partnering and product launch

Crowell & Moring, the only law firm featured at the event, will be join the following participants: Abgenix Inc.; American Heritage Fund; Amgen Inc.; Automated Cell Inc.; Avid Bioservices Inc.; Bioforesight; Bristol-Myers Squibb; Corixa Corporation; Dyax Corporation; Elusys Therapeutics; Federated-Kaufman Fund; Genzyme Corporation; COS Corporation; Kalobios Inc.; Keryx Biopharmaceuticals; Medarex Inc.; Novartis Pharmaceuticals; Redington Inc.; Seattle Genetics; Six Degrees Capital; and Synergy Advisors.

Robin has 20 years of prosecution and counseling experience in biotechnology and pharmaceutical patent law. She started her patent law career at the United States Patent and Trademark Office (USPTO), where she worked as an Assistant and Primary Patent Examiner in then newly-formed Biotechnology Group. During her eight year tenure at the USPTO, Robin examined hundreds of patent applications relating to recombinant proteins and polypeptides, vaccines, nucleic acids, vectors, novel microorganisms and cell lines, microbial and cell-based expression systems, homologous recombination, glycoproteins, fermentation, genes, ribozymes, antisense therapeutics, and gene therapy. Ms. Teskin issued several hundred patent applications including United States Patent No. 5,000,000, granted in 1991, relating to a recombinant expression system for production of ethanol. Also, while at the USPTO, Ms. Teskin received a Bronze Medal for distinguished federal service.